P. Weaver

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2010, British journal of haematology.

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2010, British journal of haematology.

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2008 .

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2008 .